Home › Brain Tumors › NCT05559853
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
Development of a Clinical CEST MR Fingerprinting Method for Treatment Response Assessment in Brain Metastases
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: Healthy volunteers \[for Study Aim 1 (SA1) and Study Aim 2 (SA2)\] will be entered into the study if they meet the following criteria: * Age ≥ 18 years * Able to understand and give informed consent * No known cancer diagnosis Patients \[for Study Aim 1 (SA1)\] will be entered into the study if they meet the following criteria: * Age ≥ 18 years * Able to understand and give informed consent * At least one untreated brain metastasis \> 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist) Patients \[for Study Aim 3 (SA3)\] will be entered into the study if they meet the following criteria: * Age ≥ 18 years * Able to understand and give informed consent * At least one untreated brain metastasis \> 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist) * Planned SRS treatment Exclusion Criteria: Healthy volunteers (SA1 \& SA2) and patients (SA1 \& SA3) exclusion criteria: * Pregnant or breastfeeding women * Pre-existing medical conditions, including the likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest * Age \< 18 years
About the study
The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therapy called stereotactic radiosurgery (SRS).
What is being tested
- CEST-MRF (diagnostic test)
Sponsor: Memorial Sloan Kettering Cancer Center · Participants: 119 · Started: Sep 22, 2022
Contact the study team
- Ouri Cohen, PhD · Phone: 646-608-8259
- Nelson Moss, MD · Phone: 212-639-7075
Official record on ClinicalTrials.gov — NCT05559853
Locations in the U.S.
| New York | Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.